These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 26432786)

  • 21. E1A-mediated inhibition of HSPA5 suppresses cell migration and invasion in triple-negative breast cancer.
    Chen HA; Chang YW; Tseng CF; Chiu CF; Hong CC; Wang W; Wang MY; Hsiao M; Ma JT; Chen CH; Jiang SS; Wu CH; Hung MC; Huang MT; Su JL
    Ann Surg Oncol; 2015 Mar; 22(3):889-98. PubMed ID: 25212833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
    Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
    Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors.
    Torres KE; Zhu QS; Bill K; Lopez G; Ghadimi MP; Xie X; Young ED; Liu J; Nguyen T; Bolshakov S; Belousov R; Wang S; Lahat G; Liu J; Hernandez B; Lazar AJ; Lev D
    Clin Cancer Res; 2011 Jun; 17(12):3943-55. PubMed ID: 21540237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma.
    Truffaux N; Philippe C; Paulsson J; Andreiuolo F; Guerrini-Rousseau L; Cornilleau G; Le Dret L; Richon C; Lacroix L; Puget S; Geoerger B; Vassal G; Östman A; Grill J
    Neuro Oncol; 2015 Jul; 17(7):953-64. PubMed ID: 25534822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 2-(4-Hydroxy-3-methoxyphenyl)-benzothiazole suppresses tumor progression and metastatic potential of breast cancer cells by inducing ubiquitin ligase CHIP.
    Hiyoshi H; Goto N; Tsuchiya M; Iida K; Nakajima Y; Hirata N; Kanda Y; Nagasawa K; Yanagisawa J
    Sci Rep; 2014 Nov; 4():7095. PubMed ID: 25403352
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disulfiram induces anoikis and suppresses lung colonization in triple-negative breast cancer via calpain activation.
    Kim JY; Lee N; Kim YJ; Cho Y; An H; Oh E; Cho TM; Sung D; Seo JH
    Cancer Lett; 2017 Feb; 386():151-160. PubMed ID: 27894956
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.
    Mehta PP; Whalen P; Baxi SM; Kung PP; Yamazaki S; Yin MJ
    Clin Cancer Res; 2011 Aug; 17(16):5432-42. PubMed ID: 21715568
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer.
    Giró-Perafita A; Palomeras S; Lum DH; Blancafort A; Viñas G; Oliveras G; Pérez-Bueno F; Sarrats A; Welm AL; Puig T
    Clin Cancer Res; 2016 Sep; 22(18):4687-97. PubMed ID: 27106068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The HGF inhibitory peptide HGP-1 displays promising in vitro and in vivo efficacy for targeted cancer therapy.
    Chen L; Li C; Zhu Y
    Oncotarget; 2015 Oct; 6(30):30088-101. PubMed ID: 26254225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
    Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
    BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic Targeting of Stromal-Tumor HGF-MET Signaling in an Organotypic Triple-Negative Breast Tumor Model.
    Singh S; Lamichhane A; Rafsanjani Nejad P; Heiss J; Baumann H; Gudneppanavar R; Leipzig ND; Konopka M; Luker GD; Tavana H
    Mol Cancer Res; 2022 Jul; 20(7):1166-1177. PubMed ID: 35348758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer.
    Weng TH; Yao MY; Xu XM; Hu CY; Yao SH; Liu YZ; Wu ZG; Tang TM; Fu PF; Wang MH; Yao HP
    Cancer Res Treat; 2020 Jul; 52(3):973-986. PubMed ID: 32324988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A.
    Breen L; Gaule PB; Canonici A; Walsh N; Collins DM; Cremona M; Hennessy BT; Duffy MJ; Crown J; Donovan NO; Eustace AJ
    Invest New Drugs; 2020 Oct; 38(5):1365-1372. PubMed ID: 32318883
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis.
    Jin K; Pandey NB; Popel AS
    Breast Cancer Res; 2018 Jun; 20(1):54. PubMed ID: 29898755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers.
    Linklater ES; Tovar EA; Essenburg CJ; Turner L; Madaj Z; Winn ME; Melnik MK; Korkaya H; Maroun CR; Christensen JG; Steensma MR; Boerner JL; Graveel CR
    Oncotarget; 2016 Oct; 7(43):69903-69915. PubMed ID: 27655711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.
    Zhang T; Prasad P; Cai P; He C; Shan D; Rauth AM; Wu XY
    Acta Pharmacol Sin; 2017 Jun; 38(6):835-847. PubMed ID: 28216624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cabozantinib Inhibits Abiraterone's Upregulation of IGFIR Phosphorylation and Enhances Its Anti-Prostate Cancer Activity.
    Wang X; Huang Y; Christie A; Bowden M; Lee GS; Kantoff PW; Sweeney CJ
    Clin Cancer Res; 2015 Dec; 21(24):5578-87. PubMed ID: 26289068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.
    Greer YE; Gilbert SF; Gril B; Narwal R; Peacock Brooks DL; Tice DA; Steeg PS; Lipkowitz S
    Breast Cancer Res; 2019 Feb; 21(1):27. PubMed ID: 30777098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
    Seitz S; Buchholz S; Schally AV; Weber F; Klinkhammer-Schalke M; Inwald EC; Perez R; Rick FG; Szalontay L; Hohla F; Segerer S; Kwok CW; Ortmann O; Engel JB
    BMC Cancer; 2014 Nov; 14():847. PubMed ID: 25410881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Signaling pathway inhibitors target breast cancer stem cells in triple-negative breast cancer.
    Li W; Yang H; Li X; Han L; Xu N; Shi A
    Oncol Rep; 2019 Jan; 41(1):437-446. PubMed ID: 30365081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.